Almirall, S.A. (BME: ALM)

Market Cap	1.87B
Revenue (ttm)	931.63M
Net Income (ttm)	-35.10M
Shares Out	213.47M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	44.71
Dividend	0.18 (2.10%)
Ex-Dividend Date	May 17, 2024

Volume	67,744
Open	8.69
Previous Close	8.76
Day's Range	8.67 - 8.73
52-Week Range	7.85 - 10.08
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Almirall

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1943
• Employees: 1,996
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ALM

Financial Performance

In 2023, Acerinox's revenue was 6.62 billion, a decrease of -24.09% compared to the previous year's 8.72 billion. Earnings were 228.13 million, a decrease of -58.97%.